BioCentury
ARTICLE | Clinical News

Pharmos, Bausch & Lomb Pharmaceuticals Inc. regulatory update

April 15, 2013 7:00 AM UTC

The FDA issued an approvable letter for the companies' NDA for PARS Lotemax (loteprodnol etabonate), an anti-inflammatory topical steroid, contingent on resolving labeling and certain technical issue...